U.S. FDA Approves IND for Ruxoprubart in DM
The U.S. Food and Drug Administration (FDA) has granted clearance for NovelMed Therapeutics’ ruxoprubart (NM8074), an investigational drug, to begin an efficacy Phase II trial to treat dermatomyositis (DM). This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with […]